Relypsa Files For IPO
Redwood City-based Relypsa has filed for an IPO, saying that it is looking to raise up to $126.5M in its initial public offering on the NASDAQ Global Market. The company, which is developing non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases, has not yet selected a trading symbol. The company's IPO is being underwritten by Morgan Stanley, BofA Merrill Lynch, Cowen and Company, Stifel, and Wedbush PacGrow Life Sciences. The company's backers include OrbiMed, 5AM Ventures, Delphi Ventures, New Leaf Ventures, Sprout Capital and Sibling Capital.
posted on Monday, September 30, 2013
Related companies:
Relypsa
Related stories:
> Relypsa Gets $80M In Series C
> Relypsa Nabs $70M
> Relypsa Gets $33M, Spins Out of Amgen-Ilypsa
> Adobe, Yahoo Add Advertising To PDF Files
> Google Docs Expands File Support
silicontap.com Home